Huoxin Pill Attenuates Cardiac Inflammation by Suppression of TLR4/NF-κB in Acute Myocardial Ischemia Injury Rats.

Jianfeng Chu,Jun Peng,Qi Li,Xueling Zhou,Aling Shen,Xintong Chen,Ali Farman,Lianli Peng,Huajian Gao,Youqin Chen,Meizhong Peng,Yan Lu,Lingling Xie

doi:10.1155/2020/7905902

Abstract

Huoxin Pill (HXP), a traditional Chinese medicine, has been prescribed widely in the treatment of coronary heart disease, angina pectoris, and other diseases. However, the possible protective mechanisms of HXP on myocardial ischemia remain unclear. In the current study, we investigated the effects and potential mechanism of HXP on myocardial ischemia and cardiac inflammation and the activation of TLR4/NF-κB pathway. Determination of electrocardiogram, echocardiography, and heart weight index (HWI) indicated that HXP treatment obviously attenuated the elevation of ST-segment, end-diastolic volume, and HWI in the AMI rat model. Enzyme-linked immunosorbent assay (ELISA) demonstrated that Huoxin Pill treatment significantly decreased the levels of CTnT, CK-MB, MDA, IL-6, and TNF-α, while it increased SOD content in serum of the AMI rat model. Moreover, hematoxylin and eosin (HE) and immunohistochemistry (IHC) staining revealed that HXP treatment alleviated pathological change, infiltration of inflammatory cells, levels of IL-6 and TNF-α, and expression of TLR4 and p-NF-κB in cardiac tissues of the AMI rat model. In conclusion, HXP treatment significantly improves cardiac function and attenuates cardiac inflammation by suppressing the activation of TLR4/NF-κB pathway in the ISO-induced AMI rat model. This study provides insights into the potential of HXP on prevention and treatment of AMI.

Highlights

Acute myocardial ischemia (AMI), a pathological myocardial state resulting from imbalance between myocardial oxygen demand and coronary blood supply [1, 2], is a common symptom of coronary heart disease and other cardiac diseases such as cardiogenic shock, free wall rupture, ventricular septal rupture, acute mitral regurgitation (MR), and other critical complications [3]
ISO was injected subcutaneously and significantly elevated ST-segment in AMI rats was observed as compared to the Sham group, which demonstrate the successful establishment of acute myocardial ischemia injury model (Figures 1(a) and 1(b))
Because Huoxin Pill (HXP) is mainly used for coronary heart disease, we explored the role of HXP in the treatment of AMI for the first time

Summary

Introduction

Acute myocardial ischemia (AMI), a pathological myocardial state resulting from imbalance between myocardial oxygen demand and coronary blood supply [1, 2], is a common symptom of coronary heart disease and other cardiac diseases such as cardiogenic shock, free wall rupture, ventricular septal rupture, acute mitral regurgitation (MR), and other critical complications [3]. In the pathophysiological processes of myocardial ischemia, heart injury can be aggravated due to the large number of inflammatory factors and oxygen free radicals [16], leading to critical syndromes such as arrhythmia and heart failure, and initiating the activation of many signaling pathways [17]. Among these pathways, the Toll-like receptors (TLRs) serve as pattern-recognition receptors at a proximal step in the innate immune response to inflammatory response [18]

Objectives

Methods

Results

Conclusion